SARS-CoV-2 Infection in Patients with a History of VITT.
作者信息
Schönborn Linda, Seck Sabrina E, Thiele Thomas, Warkentin Theodore E, Greinacher Andreas
机构信息
University Medicine Greifswald, Greifswald, Germany.
McMaster University, Hamilton, ON, Canada.
出版信息
N Engl J Med. 2022 Jul 7;387(1):88-90. doi: 10.1056/NEJMc2206601. Epub 2022 Jun 27.
Abstract
摘要
相似文献
1
SARS-CoV-2 Infection in Patients with a History of VITT.有疫苗诱导的血小板减少症（VITT）病史患者的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染
N Engl J Med. 2022 Jul 7;387(1):88-90. doi: 10.1056/NEJMc2206601. Epub 2022 Jun 27.
2
VITT with inactivated SARS-CoV-2 vaccine - index case.接种过灭活 SARS-CoV-2 疫苗的 VITT - 首例病例。
Hum Vaccin Immunother. 2022 Dec 31;18(1):2036556. doi: 10.1080/21645515.2022.2036556. Epub 2022 Mar 7.
3
Editorial: SARS-CoV-2 mRNA Vaccines and the Possible Mechanism of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT).社论：SARS-CoV-2 mRNA 疫苗与疫苗诱导的免疫性血栓性血小板减少症（VITT）的可能机制。
Med Sci Monit. 2021 Apr 26;27:e932899. doi: 10.12659/MSM.932899.
4
Immune thrombocytopenia following SARS-CoV-2 vaccination in a female: Report of one case.一名女性接种新型冠状病毒2疫苗后出现免疫性血小板减少症：1例报告。
Pediatr Blood Cancer. 2023 May;70(5):e30211. doi: 10.1002/pbc.30211. Epub 2023 Feb 1.
5
Immune Thrombocytopenic Purpura (ITP) Triggered by COVID-19 Infection and Vaccination.由新冠病毒感染和疫苗接种引发的免疫性血小板减少性紫癜（ITP）
Isr Med Assoc J. 2021 Jun;23(6):378-380.
6
Relapse of immune thrombotic thrombocytopenic purpura (iTTP) possibly triggered by COVID-19 vaccination and/or concurrent COVID-19 infection.COVID-19 疫苗接种和/或同时 COVID-19 感染可能引发免疫性血栓性血小板减少性紫癜（iTTP）复发。
BMJ Case Rep. 2022 Jul 28;15(7):e247524. doi: 10.1136/bcr-2021-247524.
7
Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura.在首次发生免疫性血小板减少性紫癜后成功进行mRNA SARS-CoV-2疫苗再次接种。
Platelets. 2022 May 19;33(4):652-653. doi: 10.1080/09537104.2022.2044463. Epub 2022 Feb 28.
8
Immune thrombocytopenic purpura after SARS-CoV-2 vaccine.新型冠状病毒2型疫苗接种后免疫性血小板减少性紫癜
Br J Haematol. 2021 Aug;194(3):547-549. doi: 10.1111/bjh.17508. Epub 2021 May 2.
9
Clinical care pathway for the evaluation of patients with suspected VITT after ChAdOx1 nCoV-19 vaccination.疑似接种 ChAdOx1 nCoV-19 后出现 VITT 患者的临床评估路径。
Blood Adv. 2022 Jun 14;6(11):3315-3320. doi: 10.1182/bloodadvances.2021006862.
10
Acute immune thrombocytopenia following SARS-CoV-2 vaccination in chronic ITP patients and a healthy individual.慢性免疫性血小板减少症患者及一名健康个体接种新型冠状病毒2疫苗后发生急性免疫性血小板减少症
Int J Hematol. 2022 Feb;115(2):293-295. doi: 10.1007/s12185-021-03235-2. Epub 2021 Oct 30.
引用本文的文献
1
Relevance of anti-platelet factor 4/heparin antibodies and platelet activation in systemic inflammatory diseases and thrombosis disorders: insight from the COVID-19 pandemic.抗血小板因子4/肝素抗体与血小板活化在全身性炎症性疾病和血栓形成疾病中的相关性：来自COVID-19大流行的见解
Res Pract Thromb Haemost. 2025 Feb 9;9(1):102701. doi: 10.1016/j.rpth.2025.102701. eCollection 2025 Jan.
2
Subsequent Vaccination against SARS-CoV-2 after Vaccine-Induced Immune Thrombotic Thrombocytopenia.疫苗诱导的免疫性血栓性血小板减少症后再次接种严重急性呼吸综合征冠状病毒2疫苗
J Clin Med. 2024 Sep 14;13(18):5462. doi: 10.3390/jcm13185462.
3
Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)-Insights from Clinical Cases, In Vitro Studies and Murine Models.疫苗诱导的免疫性血小板减少症和血栓形成（VITT）——来自临床病例、体外研究和小鼠模型的见解
J Clin Med. 2023 Sep 22;12(19):6126. doi: 10.3390/jcm12196126.
4
Vaccine-induced immune thrombotic thrombocytopenia: what do we know hitherto?疫苗诱导的免疫性血栓性血小板减少症：我们目前了解多少？
Front Med (Lausanne). 2023 May 16;10:1155727. doi: 10.3389/fmed.2023.1155727. eCollection 2023.
5
Vaccine-induced immune thrombotic thrombocytopenia.疫苗诱导的免疫性血栓性血小板减少症。
Blood. 2023 Apr 6;141(14):1659-1665. doi: 10.1182/blood.2022017696.
6
Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination.了解新冠病毒疫苗接种后伴有血小板减少的血栓形成综合征
NPJ Vaccines. 2022 Nov 9;7(1):141. doi: 10.1038/s41541-022-00569-8.
本文引用的文献
1
Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient.大多数疫苗诱导的免疫性血栓性血小板减少症中的抗 PF4 抗体是一过性的。
Blood. 2022 Mar 24;139(12):1903-1907. doi: 10.1182/blood.2021014214.
2
Interactions of Spike-RBD of SARS-CoV-2 and Platelet Factor 4: New Insights in the Etiopathogenesis of Thrombosis.SARS-CoV-2 刺突 RBD 与血小板因子 4 的相互作用：血栓形成发病机制的新见解。
Int J Mol Sci. 2021 Aug 9;22(16):8562. doi: 10.3390/ijms22168562.
3
Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein.抗血小板因子 4 抗体导致的 VITT 与 SARS-CoV-2 刺突蛋白不发生交叉反应。
Blood. 2021 Oct 7;138(14):1269-1277. doi: 10.1182/blood.2021012938.
4
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.接种 ChAdOx1 nCov-19 疫苗后发生血栓性血小板减少症。
N Engl J Med. 2021 Jun 3;384(22):2092-2101. doi: 10.1056/NEJMoa2104840. Epub 2021 Apr 9.
5
COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies.COVID-19 患者常表现出高滴度非血小板活化抗 PF4/肝素 IgG 抗体。
J Thromb Haemost. 2021 May;19(5):1294-1298. doi: 10.1111/jth.15262. Epub 2021 Apr 7.
Zotero 插件